期刊文献+

Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy 被引量:40

Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy
下载PDF
导出
摘要 Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder in primary and secondary care. It is characterised by abdominal discomfort, pain and changes in bowel habits that can have a serious impact on the patient’s quality of life. The pathophysiology of IBS is not yet completely clear. Genetic, immune, environmental, inflammatory, neurological and psychological factors, in addition to visceral hypersensitivity, can all play an important role, one that most likely involves the complex interactions between the gut and the brain (gut-brain axis). The diagnosis of IBS can only be made on the basis of the symptoms of the Rome III criteria. Because the probability of organic disease in patients fulfilling the IBS criteria is very low, a careful medical history is critical and should pay particular attention to the possible comorbidities. Nevertheless, the severity of the patient’s symptoms or concerns sometimes compels the physician to perform useless and/or expensive diagnostic tests, transforming IBS into a diagnosis of exclusion. The presence of alarming symptoms (fever, weight loss, rectal bleeding, significant changes in blood chemistry), the presence of palpable abdominal masses, any recent onset of symptoms in patient aged over 50 years, the presence of symptoms at night, and a familial history of celiac disease, colorectal cancer and/or inflammatory bowel diseases all warrant investigation. Treatment strategies are based on the nature and severity of the symptoms, the degree of functional impairment of the bowel habits, and the presence of psychosocial disorders. This review examines and discusses the pathophysiological aspects and the diagnostic and therapeutic approaches available for patients with symptoms possibly related to IBS, pointing out controversial issues and the strengths and weaknesses of the current knowledge. Irritable bowel syndrome(IBS) is the most frequently diagnosed functional gastrointestinal disorder in primary and secondary care. It is characterised by abdominal discomfort, pain and changes in bowel habits that can have a serious impact on the patient's quality of life. The pathophysiology of IBS is not yet completely clear. Genetic, immune, environmental, inflammatory, neurological and psychological factors, in addition to visceral hypersensitivity, can all play an important role, one that most likely involves the complex interactions between the gut and the brain(gut-brain axis). The diagnosis of IBS can only be made on the basis of the symptoms of the Rome Ⅲ criteria. Because the probability of organic disease in patients fulfilling the IBS criteria is very low, a careful medical history is critical and should pay particular attention to the possible comorbidities.Nevertheless, the severity of the patient's symptoms or concerns sometimes compels the physician to perform useless and/or expensive diagnostic tests, transforming IBS into a diagnosis of exclusion. The presence of alarming symptoms(fever, weight loss, rectal bleeding, significant changes in blood chemistry), the presence of palpable abdominal masses, any recent onset of symptoms in patient aged over 50 years, the presence of symptoms at night, and a familial history of celiac disease, colorectal cancer and/or inflammatory bowel diseases all warrant investigation. Treatment strategies are based on the nature and severity of the symptoms, the degree of functional impairment of the bowel habits, and the presence of psychosocial disorders. This review examines and discusses the pathophysiological aspects and the diagnostic and therapeutic approaches available for patients with symptoms possibly related to IBS, pointing out controversial issues and the strengths and weaknesses of the current knowledge.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第27期8807-8820,共14页 世界胃肠病学杂志(英文版)
关键词 Irritable bowel syndrome PATHOGENESIS DIAGNOSIS THERAPY Irritable bowel syndrome Pathogenesis Diagnosis Th
  • 相关文献

参考文献13

  • 1Magdy El-Salhy.Irritable bowel syndrome:Diagnosis and pathogenesis[J].World Journal of Gastroenterology,2012,18(37):5151-5163. 被引量:51
  • 2Antonio Bove,Filippo Pucciani,Massimo Bellini,Edda Battaglia,Renato Bocchini,Donato Francesco Altomare,Giuseppe Dodi,Guido Sciaudone,Ezio Falletto,Vittorio Piloni,Dario Gambaccini,Vincenzo Bove.Consensus statement AIGO/SICCR:Diagnosis and treatment of chronic constipation and obstructed defecation(partⅠ:Diagnosis)[J].World Journal of Gastroenterology,2012,18(14):1555-1564. 被引量:20
  • 3Massimo Bellini,Angelo Gemignani,Dario Gambaccini,Simona Toti,Danilo Menicucci,Cristina Stasi,Francesco Costa,Maria Gloria Mumolo,Angelo Ricchiuti,Remo Bedini,Nicola de Bortoli,Santino Marchi.Evaluation of latent links between irritable bowel syndrome and sleep quality[J].World Journal of Gastroenterology,2011,17(46):5089-5096. 被引量:17
  • 4Jessica R. Biesiekierski,Simone L. Peters,Evan D. Newnham,Ourania Rosella,Jane G. Muir,Peter R. Gibson.No Effects of Gluten in Patients With Self-Reported Non-Celiac Gluten Sensitivity After Dietary Reduction of Fermentable, Poorly Absorbed, Short-Chain Carbohydrates[J].Gastroenterology.2013(2)
  • 5Lena ?hman,Magnus Simrén.Intestinal Microbiota and its Role in Irritable Bowel Syndrome (IBS)[J].Current Gastroenterology Reports.2013(5)
  • 6M. B. O. Lowén,E. A. Mayer,M. Sj?berg,K. Tillisch,B. Naliboff,J. Labus,P. Lundberg,M. Str?m,M. Engstr?m,S. A. Walter.Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome[J].Aliment Pharmacol Ther.2013(12)
  • 7Cristina Stasi,Massimo Rosselli,Massimo Bellini,Giacomo Laffi,Stefano Milani.Altered neuro-endocrine–immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model[J].Journal of Gastroenterology.2012(11)
  • 8E. M. M. Quigley,J. Tack,W. D. Chey,S. S. Rao,J. Fortea,M. Falques,C. Diaz,S. J. Shiff,M. G. Currie,J. M. Johnston.Randomised clinical trials: linaclotide phase 3 studies in IBS ‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints[J].Aliment Pharmacol Ther.2012(1)
  • 9J. Matricon,M. Meleine,A. Gelot,T. Piche,M. Dapoigny,E. Muller,D. Ardid.Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome[J].Aliment Pharmacol Ther (pt).2012(11pt12)
  • 10Jacqueline S. Barrett,Peter R. Gibson.Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?[J].Therapeutic Advances in Gastroenterology.2012(4)

二级参考文献7

共引文献99

同被引文献311

引证文献40

二级引证文献295

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部